Effects of β-Lactamases and \textit{omp} Mutation on Susceptibility to β-Lactam Antibiotics in \textit{Escherichia coli}

MASAKI HIRAOKA,†* RYIOICHI OKAMOTO, MatsuhisA INOUE, AND SUSUMU MITSUHASHI

Episome Institute, Kogure 2220, Fugimi-mura, Seta-gun, Gunma 371-01, and Laboratory of Drug Resistance in Bacteria, School of Medicine, Gunma University, Shouwamachi 3-39-22, Maebashi 371, Japan

Received 15 July 1988/Accepted 6 December 1988

Four types of β-lactamases consisting of a penicillinase type I (TEM-1), a penicillinase type II (OXA-1), a cephalosporinase of \textit{Citrobacter freundii}, and a cephalosporinase of \textit{Proteus vulgaris} were introduced into \textit{Escherichia coli} MC4100 and its \textit{omp} mutants, MH1160 (MC4100 \textit{ompR}) and MH760 (MC4100 \textit{ompR}2), by transformation. Effects of the combination of the \textit{omp} mutations and these β-lactamases on the susceptibility of \textit{E. coli} strains were studied with 15 β-lactam antibiotics including cephalosporins, cephamycins, penicillins, imipenem, and aztreonam. The \textit{ompR} mutant, MH1160, lacks OmpF and OmpC, and it showed reduced susceptibility to 11 of the 15 β-lactam agents. The reduction in susceptibility to cefoxitin, moxalactam, and flomoxef was much greater than reduction in susceptibility to the other agents. When the \textit{ompR} mutant produced the cephalosporinase of \textit{C. freundii}, the susceptibility of the mutant to 12 of the 15 β-lactam antibiotics decreased. The reduction in susceptibility of MH1160 to 10 of the 12 agents affected by the enzyme was two- to fourfold greater than that observed in MC4100. Such a synergistic effect was also observed with the cephalosporinase of \textit{P. vulgaris} and \textit{ompR} mutation against six cephalosporins, moxalactam, and aztreonam.

β-Lactamases of gram-negative bacteria play an important part in bacterial resistance to β-lactam antibiotics. They are mediated by chromosomally or plasmidic expression of β-lactamases, i.e., amount of the enzymes, and substrate profiles of the enzymes are major factors that determine resistance levels. Also, permeability of β-lactam antibiotics through the bacterial outer membrane affects susceptibility to β-lactam agents (21). Since OmpF and OmpC porins of \textit{Escherichia coli} were found to act as pores for diffusion through the outer membrane, the role of the porin channels in permeation of β-lactams has been studied actively (24, 29). Some β-lactam antibiotics, e.g., cefoxitin, are known to penetrate much more rapidly through the OmpF porin than through the OmpC porin (11). Decreased permeability of the outer membrane and alterations in the outer membrane proteins also have been studied as factors in resistance to β-lactam antibiotics (1, 6, 12). Recently, the contributions of β-lactamases and outer membrane permeability to resistance have been studied simultaneously (15, 20, 27). Such an approach is more appropriate when both hydrolytic rate and permeation rate are slow (5). In our studies on bacterial resistance to newer cephalosporins by cephalosporinases, a decrease in permeability intensifies the reduction in antimicrobial activity by cephalosporinase against cefotaxime and cefadizime in \textit{E. coli} (7, 8). For the elucidation of the resistance mechanisms and the evaluation of new agents, studies on the effects of β-lactamase production on bacterial susceptibility of the mutants with altered outer membrane permeability should yield important information.

In this study, we chose four β-lactamases with different substrate profiles, two penicillinases and two cephalosporinases, and we also chose as substrates 15 β-lactam antibiotics including eight cephalosporins, two penicillins, two oxacephemycins, a cephamycin, a carbapenem, and a monobactam. The effect of β-lactamase production on susceptibility to β-lactam antibiotics was tested in \textit{E. coli} \textit{omp} mutants that lack OmpC or both OmpF and OmpC.

**MATERIALS AND METHODS**

\textbf{Bacteria and plasmids.} \textit{E. coli} MC4100 (\textit{F} \textit{lacU169 araD139 rpsL relA thiA fibB}1), MH1160 (MC4100 \textit{ompR}), and MH760 (MC4100 \textit{ompR}2) were kindly donated by S. Mizushima (Nagoya University, Nagoya, Japan). MH1160 and MH760 are \textit{omp} mutants of MC4100. MH1160 lacks outer membrane proteins OmpF and OmpC (4). MH760 lacks OmpC and produces OmpF constitutively, while the parent strain MC4100 has osmoregulated production of OmpF and OmpC (3). Four plasmids, pMS510 and pMS509 (R. Okamoto, S. Mitsuhashi, and M. Inoue, unpublished results), pMS185-2, and pMS182-5, are derivatives of pACYC184 (2) and contain cloned β-lactamase genes of the following types: penicillinase type I (TEM-1) of Rms212 (28), penicillinase type II (OXA-1) of Rms213 (28), cephalosporinase of \textit{Citrobacter freundii} GN346 (26), oxyimino-cephalosporinase of \textit{Proteus vulgaris} GN7919 (16), respectively. pMS510 has an \textit{EcoRI} fragment (14.5 kilobases [kb]) of Rms212 in the \textit{EcoRI} site of pACYC184. pMS509 has an \textit{EcoRI} fragment (7.4 kb) of Rms213 in the \textit{EcoRI} site of pACYC184. The chromosomal cephalosporinase gene of \textit{C. freundii} GN346 was cloned into the \textit{EcoRI} site of pACYC184 to produce pMS185, which mediates inducible production of \textit{C. freundii} cephalosporinase. pMS185-2 is a deletion derivative of pMS185 obtained by the use of \textit{AccI} and contains a 4.8-kb fragment from the \textit{C. freundii} chromosome. First, the chromosomal cephalosporinase gene of \textit{P. vulgaris} GN7919 was cloned into the \textit{EcoRI} site of pACYC184 to yield pMS182 (14), which mediates inducible production of \textit{P. vulgaris} cephalosporinase. Second, the cephalosporinase gene of MS182 was recloned into the same vector by the use of \textit{HaeII} to produce pMS182-5, which contains a 6.35-kb fragment from the \textit{P. vulgaris} chromosome. Transformants

* Corresponding author.
† Present address: Preclinical Research Laboratories, Bristol-Myers Research Institute, Futagoyama 1, Sakazaki, Kota-cho, Nukata-gun, Aichi 444-01, Japan.
TABLE 1. β-Lactamase activity of *E. coli* strains with cloned β-lactamase genes

<table>
<thead>
<tr>
<th>Strain&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Plasmid</th>
<th>Enzyme&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Enzyme activity (nkat/mg of protein)&lt;sup&gt;c&lt;/sup&gt;</th>
<th>MIC (µg/ml)&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>ABPC</td>
<td>CET</td>
</tr>
<tr>
<td>MC4100 (F&lt;sup&gt;+&lt;/sup&gt; C&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>Host</td>
<td>None</td>
<td>—</td>
<td>1.56</td>
</tr>
<tr>
<td></td>
<td>pMS510</td>
<td>PCase type I</td>
<td>55</td>
<td>1,600</td>
</tr>
<tr>
<td></td>
<td>pMS509</td>
<td>PCase type II</td>
<td>13</td>
<td>6,400</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CCase</td>
<td>0.82</td>
<td>6.25</td>
</tr>
<tr>
<td></td>
<td>pMS182-5</td>
<td>CXase</td>
<td>3.4</td>
<td>1,600</td>
</tr>
<tr>
<td>MH1160 (F&lt;sup&gt;+&lt;/sup&gt; C&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>Host</td>
<td>None</td>
<td>—</td>
<td>3.13</td>
</tr>
<tr>
<td></td>
<td>pMS510</td>
<td>PCase type I</td>
<td>28</td>
<td>3,200</td>
</tr>
<tr>
<td></td>
<td>pMS509</td>
<td>PCase type II</td>
<td>5.1</td>
<td>6,400</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CCase</td>
<td>0.88</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>pMS182-5</td>
<td>CXase</td>
<td>3.6</td>
<td>3,200</td>
</tr>
<tr>
<td>MH760 (F&lt;sup&gt;+++&lt;/sup&gt; C&lt;sup&gt;+++&lt;/sup&gt;)</td>
<td>Host</td>
<td>None</td>
<td>—</td>
<td>1.56</td>
</tr>
<tr>
<td></td>
<td>pMS510</td>
<td>PCase type I</td>
<td>28</td>
<td>1,600</td>
</tr>
<tr>
<td></td>
<td>pMS509</td>
<td>PCase type II</td>
<td>5.5</td>
<td>3,200</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CCase</td>
<td>1.1</td>
<td>6.25</td>
</tr>
<tr>
<td></td>
<td>pMS182-5</td>
<td>CXase</td>
<td>3.3</td>
<td>1,600</td>
</tr>
</tbody>
</table>

<sup>a</sup> F<sup>+</sup> and C<sup>+</sup>, Lack of OmpF and OmpC, respectively; F<sup>+++</sup> and C<sup>+++</sup>, omsoregulated production of OmpF and OmpC, respectively; F<sup>+++</sup>, constitutive production of OmpF.

<sup>b</sup> PCase, Penicillinase; CCase, cephalosporinase of *C. freundii*; CXase, cephalosporinase of *P. vulgaris*.

<sup>c</sup> Less than 0.08 nkat/mg for ampicillin and less than 0.05 nkat/mg for cefalothin.

<sup>d</sup> ABPC, Ampicillin; CET, cefalothin.

with pMS185-2 or pMS182-5 produced cephalosporinas constitutively. These plasmids were introduced into *E. coli* MC4100, MH1160, and MH760 by transformation. The transformants of MC4100 and MH1160 with pMS185-2 or pMS182-5 were reported previously (7).

**Antibiotics.** Antibiotics were obtained from the following companies: cefoxitin and imipenem, Banyu Pharmaceutical Co., Ltd.; cefepime (BMY-28142), Bristol-Myers Research Institute; cefotaxime, Fujisawa Pharmaceutical Co., Ltd.; ceftizoxime and ceftiramide (HR810), Hoechst Japan Ltd.; ampicillin, Meiji Seika Kaisha Ltd.; cefuroxime and ceftazidime, Shioninohitsujo Co., Ltd.; cefalothin, moxalactam, and flomoxef, Shionogi & Co., Ltd.; aztreonam, Squibb Japan Inc.; and piperacillin and ceftazidime, Toyama Chemical Co., Ltd.

**β-Lactamase assay.** The β-lactamase activities of *E. coli* strains were determined by a spectrophotometric method (18) at 30°C in 50 mM phosphate buffer (pH 7.0) with ampicillin (100 µM) as the substrate for penicillinases and cefalothin (100 µM) as the substrate for the cephalosporinas. Enzyme activity was expressed as nanomoles of substrate hydrolyzed per second (nanokatals) by 1 mg of protein of bacterial crude extract prepared by sonication. Protein concentration was determined by the method of Lowry et al. (13) with bovine serum albumin as the standard.

**SDS-urea-PAGE.** Outer membrane proteins of the strains of *E. coli* before and after transformation were confirmed by sodium dodecyl sulfate-urea-polyacrylamide gel electrophoresis (SDS-urea-PAGE) (19). The outer membrane fraction was prepared by the method of Inokuchi et al. (9) as a Sarkosyl-insoluble fraction. Penassay broth (Difco Laboratories) was used for a bacterial culture medium.

**Susceptibility testing.** Susceptibilities of the *E. coli* strains to various β-lactam antibiotics were determined by an agar dilution method in sensitivity test agar (Nissui Seiyaku), i.e., modified Mueller-Hinton agar. Approximately 10<sup>4</sup> CFU of bacterial culture was inoculated onto agar plates containing serial twofold dilutions of the agents. MIC was scored after incubation for 18 h at 37°C. When a difference in MICs of an agent between two strains was fourfold or greater, the difference was considered significant.

**RESULTS**

**β-Lactamase activities of the transformants.** Table 1 shows β-lactamase activities of *E. coli* MC4100, MH1160, and MH760 and their transformants and MICs of ampicillin and cefalothin for the strains. The expression of the cephalosporinas mediated by pMS185-2 or pMS182-5 was almost the same among the transformants of MC4100, MH1160, and MH760, whereas the penicillinase activities, which were mediated by pMS510 and pMS509, of MH1160 and MH760 were about half of those of the transformants of MC4100. Susceptibility of the *E. coli* strains to ampicillin or cefalothin decreased significantly after transformation.

**SDS-urea-PAGE of outer membrane proteins.** The outer membrane proteins of the transformants were compared with those of the host strains. Figure 1 shows SDS-urea-PAGE patterns of the outer membrane proteins from the strains before and after transformation with pMS185-2 or pMS182-5. The strains containing pMS510 or pMS509 gave results comparable to those of the strains containing pMS185-2 or pMS182-5. MC4100 produced both OmpF and OmpC. MH1160 did not produce either OmpF or OmpC. MH760 did not produce OmpC and produced much more OmpF than did MC4100. The outer membrane proteins of the strains did not change after transformation.

**Susceptibilities of the *E. coli* strains with and without β-lactamases to various β-lactam antibiotics.** Susceptibilities of *E. coli* MC4100, its omp mutants, and their transformants with β-lactamases were tested against the following 13 β-lactam antibiotics in addition to ampicillin and cefalothin (Table 2; see Table 1 for susceptibilities to ampicillin and cefalothin): seven cephalosporins, i.e., cefeporazone, cefotizoxime, ceftizoxime, cefotaxime, ceftazidime, ceftipime, and cepime; a penicillin, piperacillin; two oxacephemycins, moxalactam and flomoxef; a cephapenic, cefoxitin; a carbapenem, imipenem; and a monobactam, aztreonam.
(i) Decrease in susceptibility by ompR1 mutation. A decrease in susceptibility by ompR1 mutation was observed with 11 of the 15 β-lactams tested but not with ampicillin, piperacillin, or imipenem. The activities of cefoxitin, moxalactam, and flomoxef were most affected by the mutation, and their MICs for MH1160 were 16-fold those for MC4100.

(ii) Decrease in susceptibility of MC4100 by production of β-lactamases. The type I penicillinase significantly reduced the activities of ampicillin, piperacillin, and ceftazidime but reduced only slightly or not at all the activities of the other β-lactam antibiotics. The type II penicillinase greatly reduced the activity of the penicillins, resulting in a more than 500-fold increase in MIC, and also reduced the activity of six cephalosporins, i.e., cepfime and cepfirome (128-fold increase in MIC), cefitoxime (32-fold increase in MIC), ceftoperazone (16-fold increase in MIC), cefotaxime (16-fold increase in MIC), and cefuroxime (8-fold increase in MIC). The cephalosporinase of C. freundii reduced the activity of 10 of the 15 β-lactam agents. The increase in MIC was 16-fold for cephaparin and cefitoxime; 8-fold for cefotaxin, flomoxef, and cefuroxime; and 4-fold for ampicillin, piperacillin, ceftazidime, and aztreonam. Cefpime, cefpirome, cefuroxime, moxalactam, and imipenem were slightly or not affected by the enzyme in MC4100. The cephalosporinase of P. vulgaris reduced the activity of 11 of the 15 β-lactam agents. This enzyme affected aztreonam and all cephalosporins and penicillins tested. Among these cephalosporins, reduction in activity by the enzyme was smaller for ceftazidime, cefpime, and cefpirome than for the other seven cephalosporins; ceftazidime, cefpirome, and cepitoxime showed an increase in MIC of less than or equal to 16-fold. The reduction in antimicrobial activity was not significant for cefotaxin, moxalactam, flomoxef, or imipenem.

(iii) Combined effects of β-lactamase production and omp mutation. The greater increase in MIC for MH1160 than for MC4100 was considered due to a synergistic effect ofompR1 mutation with β-lactamases. Synergistic effect of the C. freundii cephalosporinase and ompR1 mutation was observed for 10 of the 12 β-lactams affected by the enzyme. A similar effect was observed with the P. vulgaris enzyme against 8 of 12 agents. Against ampicillin and piperacillin, type I and type II penicillinases and the P. vulgaris cephalosporinase did not show such a synergistic effect. Although the penicillinases affected antimicrobial activity synergistically withompR1 mutation against three of four cephalosporins (by type I penicillinase) and three of seven cephalosporins (by type II penicillinase), the synergistic effect was less distinct than those observed with the two cephalosporinases. The combined effects of β-lactamases and omp mutation on bacterial susceptibility were more significant when they

![OmpC and OmpF](http://aac.asm.org/)

**TABLE 2. Susceptibility of E. coli omp mutants and their β-lactamase-producing transformants to β-lactam antibiotics**

<table>
<thead>
<tr>
<th>Strain&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Plasmid&lt;sup&gt;b&lt;/sup&gt;</th>
<th>β-Lactamase&lt;sup&gt;c&lt;/sup&gt;</th>
<th>MIC (µg/ml)&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>PIPC</td>
<td>CFX</td>
</tr>
<tr>
<td>MC4100 (F&lt;sup&gt;+&lt;/sup&gt; C&lt;sup&gt;+&lt;/sup&gt;)</td>
<td>Host</td>
<td>None</td>
<td>0.20</td>
</tr>
<tr>
<td></td>
<td>pMS107</td>
<td>PCase I</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CCase</td>
<td>0.78</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CXase</td>
<td>1.00</td>
</tr>
<tr>
<td>MH1160 (F&lt;sup&gt;−&lt;/sup&gt; C&lt;sup&gt;−&lt;/sup&gt;)</td>
<td>Host</td>
<td>None</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>pMS107</td>
<td>PCase I</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CCase</td>
<td>1.56</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CXase</td>
<td>1.00</td>
</tr>
<tr>
<td>MH760 (F&lt;sup&gt;+&lt;/sup&gt; C&lt;sup&gt;−&lt;/sup&gt;)</td>
<td>Host</td>
<td>None</td>
<td>0.39</td>
</tr>
<tr>
<td></td>
<td>pMS107</td>
<td>PCase I</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>pMS185-2</td>
<td>CCase</td>
<td>0.78</td>
</tr>
</tbody>
</table>

<sup>a</sup> F<sup>−</sup> and C<sup>−</sup>: Lack of OmpF and OmpC, respectively; F<sup>+</sup> and C<sup>+</sup>: constitutive production of OmpF and OmpC, respectively.

<sup>b</sup> PCase I, Penicillinase type I (TEM-1) of Rms212; PCase II, penicillinase type II (OXA-1) of Rms212; CCase, cephalosporinase of C. freundii GN346; CXase, cephalosporinase of P. vulgaris GN7919.

<sup>c</sup> PIPC, cefpirome; CFX, cefotaxime; LMOX, moxalactam; FMOX, flomoxef; IPM, imipenem; AZT, aztreonam; CZX, cefazidime; CZX, cefpirome; CPRM, cefpirome; CFPM, cefpirome.

<sup>d</sup> Asterisks indicate fourfold (**) and greater than fourfold (***) increases in MICs for MH1160 containing these plasmids over MICs for MC4100 containing the corresponding plasmids. AZT, aztreonam; CAZ, cefazidime; CFPM, cefpirome; CFX, cefotaxim; CPRM, cefpirome; CPZ, cefoperazone; CTX, cefotaxim; CXM, cefuroxime; CZX, cefitoxime; FMOX, flomoxef; LMOX, moxalactam; IPM, imipenem; PIPC, piperacillin.
were compared between MH1160 and MH760. MH760 showed a susceptibility to β-lactam antibiotics equal to or somewhat higher than that of MC4100, and its transformants were more susceptible to some of the β-lactam antibiotics than the transformants of MC4100.

DISCUSSION

The OmpF- and OmpC-deficient mutant of E. coli, MC4100 ompR1, showed reduced susceptibility to certain β-lactam antibiotics, including cephapreoids, oxacephyramcins, cefoxitin, and aztreonam. The reduction of susceptibility was much more extensive for cefoxitin and oxacephyramcins than for other β-lactam antibiotics. Cephapreoids showed relatively less increase in MIC after the mutation than did the cephapreoids. These observations agree with the results of other investigators (11, 12). The lower susceptibility of OmpF- and OmpC-deficient mutants has been considered due to the lower permeability of β-lactam antibiotics through their outer membranes (6). Although the increase in MIC of the cephapreoids and aztreonam was small, i.e., an eightfold or smaller increase, it augmented the reduction in antimicrobial activity by β-lactamases: the increase in MIC by the cephalosporinases of C. freundii and P. vulgaris was two- to fourfold greater than the additive effects of the ompR1 mutation and the β-lactamases. The enhancement of resistance due to β-lactamases in MH1160 (OmpF- OmpC-) was significant against cephapreoids and aztreonam but not against penicilines and imipenem. These facts indicate a much greater dependency of cephapreoids and aztreonam than penicilines and imipenem on the OmpF and OmpC porins in penetration through the outer membrane. Such synergistic effects were less significant with the two penicilines, type I (TEM-1) and type II (OXA-1), probably because the expression of the penicilines in the omp mutant was about half that in the parent strain, for unknown reasons. The lack of OmpC alone apparently did not result in enhancement of β-lactamase-mediated resistance in MH760 (OmpC- OmpF++), which still produces OmpF constitutively. However, OmpC- mutants with osmoregulated OmpF would behave as OmpF- and OmpC- mutants under high-osmolarity circumstances (17).

A recent problem in β-lactam chemotherapy is the existence or the emergence of multiple β-lactam-resistant strains of gram-negative bacteria, e.g., Enterobacter cloacae, C. freundii, Serratia marcescens, and Pseudomonas aeruginosa, which overproduce chromosomal cephalosporinases (22). When the ompR1 mutant produced the cephalosporinase of C. freundii, it showed decreased susceptibility to almost all β-lactam antibiotics, except for imipenem, compared with the parent. Among these β-lactam agents, cefepime and ceftirome showed much greater activity than other agents. This greater activity is mainly due to their much greater stability against the cephalosporinases at a low concentration which is still enough to inhibit penicillin-binding proteins, because of the low affinity of the enzymes for both agents (8, 23). Neither production of these β-lactamases nor ompR1 mutation significantly affected the activity of imipenem. These observations indicate high permeability of imipenem through the outer membrane (7) and a possibility that imipenem penetrates into periplasmic space through an alternative pathway, as discussed by Jaffe et al. (11). Our results confirm the observation of Jacoby and Sutton (10) that some TEM-type and OXA-type enzymes and E. coli cephalosporinase affect the activity of newer broad-spectrum β-lactam antibiotics such as cefotaxime, ceftazidime, cefepime, and aztreonam. They also studied effects of β-lactamases in omp mutant strains. However, our results revealed more clearly the synergistic effects of lowered permeability and β-lactamase production on bacterial susceptibility.

Substrate profiles of β-lactamases are major factors in resistance. In fact, the P. vulgaris cephalosporinase possesses a broad substrate profile, ranging from penicilines to cephapreoids including oxyimino-cephalosporins (16), and this cephalosporinase reduced antimicrobial activity of penicilines, cephapreoids, and aztreonam in E. coli (Table 2). Among the β-lactam antibiotics we tested, the low-permeability strain, MH1160, with the P. vulgaris enzyme was still susceptible to cefepime, ceftizoxime, flomoxef, imipenem, and moxalactam: the MICs were lower than 6.25 μg/ml. Since a derepressed and overproducing mutant of P. vulgaris was still susceptible to cefotaxime and ceftazidime (7), the chromosomal cephalosporinase of P. vulgaris has less clinically significant resistance to the newer-generation cephalosporins. Recently, however, a new type of plasmid-mediated β-lactamase with a broad substrate spectrum was reported, i.e., CTX-1 (25), which is similar to the P. vulgaris enzyme in hydrolysis of cefotaxime and inhibition by clavulanic acid. These broad-spectrum β-lactamases may become more important factors in the resistance to β-lactam antibiotics. Our set of E. coli strains should be useful for evaluation of β-lactam antibiotics because it combines both a variety of β-lactamases and β-lactam permeability in isogenic strains.

LITERATURE CITED